Tonix制药控股 TNXP 深 沪
等待开盘 10-29 09:30:00 美东时间
19.47
-0.880
-4.32%
华盛通- 最 高20.4896
- 今 开20.40
- 成交量 85.48万股
- 最 低 18.85
- 昨 收 20.35
- 总市值 36.39亿
- 52周最高 130.00
- 市盈率 静 --
- 换手率 0.46%
- 52周最低 6.76
- 委 比 -52.94%
- 总股本 1.87亿
- 历史最高 13440000000.00
- 量 比 1.40
- 振 幅 8.06%
- 历史最低 15.00
- 每 手 1
- 风险率 11.76%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Tonix Pharmaceuticals Announces Presentation at BIO-Europe 2025
Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) announced that CEO Seth Lederman, M.D., will present at BIO-Europe 2025 in Vienna, Austria on November 4, 2025. The presentation will focus on Tonix's strategy, pipeline, and upcoming milestones. Tonix, a biopharmaceutical company, has received FDA approval for TonmyaTM, a non-opioid analgesic for fibromyalgia, the first new prescription medicine for the condition in over 15 years. The company's ...
10-28 11:00
Tonix Pharmaceuticals Announces First Patient Dosed in the Investigator-Initiated FOCUS Study of Tonix’s Intranasal Potentiated Oxytocin in AVP-D Conducted by Massachusetts General Hospital
Tonix Pharmaceuticals has initiated the FOCUS study to evaluate intranasal potentiated oxytocin products (TNX-1900/TNX-2900) in patients with arginine-vasopressin deficiency (AVP-D), a rare disorder linked to oxytocin deficiency and mental health challenges. The randomized, double-blind, placebo-controlled crossover pilot trial aims to assess the effects of single and two-week doses of oxytocin on anxiety, depression, and socioemotional functioni...
10-22 11:00
Tonix Pharmaceuticals to Present Poster on Tonmya™ at the 2025 American College of Rheumatology (ACR) Convergence
Tonix Pharmaceuticals announced that Dr. Gregory Sullivan will present a poster on Tonmya™ (cyclobenzaprine HCl sublingual tablets) at the 2025 American College of Rheumatology Convergence in Chicago. The presentation will highlight Tonmya's effectiveness in reducing pain and its favorable tolerability in fibromyalgia patients. Tonmya is FDA-approved as a first-in-class, non-opioid treatment for fibromyalgia and is part of Tonix's pipeline target...
10-21 11:00
Tonix Pharmaceuticals Presented Data on TNX-801 Mpox Vaccine at World Vaccine Congress–Europe 2025
<p>TNX-801 is a live, attenuated horsepox-based investigational vaccine designed to protect against mpox and smallpox. Preclinical data show it induces durable immune responses, prevents clinical disease, and is well-tolerated across multiple delivery routes. The vaccine has demonstrated long-term protection in animal models and is advancing toward clinical development. Tonix Pharmaceuticals has received FDA feedback supporting its potential and ...
10-17 11:00
Tonix Pharmaceuticals Presented an Update on Fc-modified anti-CD40L mAb, TNX-1500, at the 61st Annual Congress of the Japan Society for Transplantation
Tonix Pharmaceuticals' CEO, Seth Lederman, presented on anti-CD154 monoclonal antibody immunomodulation at the Japan Society for Transplantation's annual congress. The talk highlighted TNX-1500, a third-generation monoclonal antibody targeting CD40L, with promising Phase 1 safety and biomarker data. TNX-1500 is being developed to prevent organ transplant rejection and treat autoimmune diseases. Lederman emphasized the role of T-regulatory cells, ...
10-14 11:00
Tonix Pharmaceuticals to Present and Participate in Panel Discussion at World Vaccine Congress, Europe 2025
Tonix Pharmaceuticals Holding Corp. announced that Dr. Sina Bavari and Dr. Zeil Rosenberg will participate in the World Vaccine Congress–Europe 2025 in Amsterdam. Dr. Bavari will present on the safety and efficacy of the TNX-801 mpox vaccine, while both will engage in a panel discussion on enhancing vaccine effectiveness using mpox as a model. The event takes place October 14–16, 2025. Tonix is a biotech company advancing treatments for fibromyal...
10-09 11:00
Tonix Pharmaceuticals Further Strengthens Commercial Leadership Team with Appointment of Ganesh Kamath as Head of Market Access
Tonix Pharmaceuticals appoints Ganesh Kamath as Head of Market Access. Mr. Kamath brings over 25 years of experience in market access, pricing, and commercial operations. The U.S. FDA recently approved Tonmya™ for fibromyalgia, the first new therapy in over 15 years. The product is expected to launch in the fourth quarter of 2025. Tonix is a biotech company focused on CNS disorders, immunology, oncology, rare diseases, and infectious diseases, wi...
09-30 12:30
Tonix Pharma Plans To Progress TNX-2900 Program For Treatment Of PWS Into Phase 2 Clinical Trial
Phase 2 randomized, double-blind, placebo-controlled trial planned to evaluate TNX-2900 in children and adolescents (ages 8 to 17.5 years) with Prader-Willi Syndrome under a cleared INDTNX-2900 granted Orphan Drug and Rare Pediatric Disease Designations by the FDA, providing the potential for a Priority Review Voucher upon approval
09-29 19:08
Tonix Pharmaceuticals Plans to Initiate Prader-Willi Syndrome Phase 2 Trial of TNX-2900 (Intranasal Potentiated Oxytocin) in 2026
Tonix Pharmaceuticals plans to advance TNX-2900, a magnesium-potentiated intranasal oxytocin formulation, into a Phase 2 clinical trial for children and adolescents with Prader-Willi Syndrome (PWS). TNX-2900 aims to improve receptor binding consistency and reduce off-target effects. The FDA has granted it Orphan Drug and Rare Pediatric Disease Designations, making Tonix eligible for a Priority Review Voucher upon approval. The trial will assess s...
09-29 11:00
Tonix Pharma Completes FDA Meeting for TNX-102 SL
Tonix Pharma ( ($TNXP) ) has shared an announcement. On September 18, 2025, Ton...
09-18 20:28
